MarketPeel
Insider Trading Intelligence
CF

Christopher James Frankenfield

XLO
CHIEF FINANCIAL OFFICER · XILIO THERAPEUTICS, INC. · CIK 0001988344
FILING MIX · LIFETIME58%/42%
BUYS
18
SELLS
13
TOTAL VALUE
$11.4K
COMPANIES
1
ACTIVE SINCE
Aug 2023
HOLDINGS NOW
24,766
AVG SELL PX
$0.81
TRADE KIND
SHOWING 31 / 31
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Christopher James Frankenfield, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%+2.93%+1.21%+1.72%+1.72%
14d2+50.00%+0.89%+1.22%-0.33%-0.33%
30d2+100.00%-23.31%+2.37%-25.67%-25.67%
60d2+100.00%-18.43%-0.28%-18.14%-18.14%
90d2+100.00%-20.61%-3.58%-17.04%-17.04%
180d2+50.00%-16.70%+7.64%-24.34%-24.34%
1y2(1 pending)+100.00%-37.20%+17.20%-54.40%-54.40%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XLO · 24,766 shares · as of Jan 2, 2026
0231,250462,500693,750925,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 18 buys / 13 sellsCOVERAGE · 11 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
XLO
XILIO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,030$0.64$4.5K24,766Jan 2, 2026Jan 5, 2026View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
19,37538,750Jan 1, 2026Jan 5, 2026View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
19,37531,796Jan 1, 2026Jan 5, 2026View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
668,789668,789Dec 31, 2025Jan 5, 2026View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
23,7860Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000300,000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
37,2960Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,78623,786Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
155,0900Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
20,0000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
45,0000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,29637,296Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
117,000117,000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,00020,000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALEGRANT
Stock grant
155,090155,090Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,00045,000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
117,0000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
300,0000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
925,000925,000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
150,0000Nov 21, 2025Nov 25, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,00075,000Apr 15, 2025Apr 16, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,954$0.98$6.8K12,421Jan 2, 2025Jan 3, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
251,000251,000Jan 1, 2025Jan 3, 2025View →
XLO
XILIO THERAPEUTICS, INC.
SALE
Chief Financial Officer
19,37558,125Jan 1, 2025Jan 3, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
19,37519,375Jan 1, 2025Jan 3, 2025View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
52,00052,000Aug 3, 2024Aug 6, 2024View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
208,000208,000May 1, 2024May 3, 2024View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
77,50077,500Jan 1, 2024Jan 3, 2024View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000300,000Aug 16, 2023Aug 18, 2023View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Aug 3, 2023Aug 7, 2023View →
Other insiders · XLO
Loading peer insiders…
About this filer
CIK 0001988344
ROLE
Chief Financial Officer
PRIMARY
XLO
COMPANIES
1
ACTIVE SINCE
Aug 2023
MARKETPEEL · /INSIDER/0001988344DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback